Now that Zymeworks BC Inc’s volume has hit 0.72 million, investors get a glimpse of its size.

On Tuesday, Zymeworks BC Inc (NASDAQ: ZYME) was 3.49% up from the session before settling in for the closing price of $11.75. A 52-week range for ZYME has been $7.97 – $17.70.

A company in the Healthcare sector has jumped its sales by 273.04% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -3.28%. With a float of $67.30 million, this company’s outstanding shares have now reached $68.96 million.

In an organization with 286 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 50.29%, operating margin of -157.03%, and the pretax margin is -152.82%.

Zymeworks BC Inc (ZYME) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zymeworks BC Inc stocks. The insider ownership of Zymeworks BC Inc is 4.07%, while institutional ownership is 98.11%. The most recent insider transaction that took place on Apr 16 ’25, was worth 825,589. In this transaction Director of this company bought 73,953 shares at a rate of $11.16, taking the stock ownership to the 17,773,727 shares. Before that another transaction happened on Apr 17 ’25, when Company’s Director bought 54,760 for $11.52, making the entire transaction worth $630,819. This insider now owns 17,828,487 shares in total.

Zymeworks BC Inc (ZYME) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.14% during the next five years compared to 15.81% growth over the previous five years of trading.

Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators

You can see what Zymeworks BC Inc (ZYME) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.18.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -0.93 in one year’s time.

Technical Analysis of Zymeworks BC Inc (ZYME)

Let’s dig in a bit further. During the last 5-days, its volume was 0.63 million. That was better than the volume of 0.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 93.71%. Additionally, its Average True Range was 0.76.

During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 38.93%, which indicates a significant decrease from 96.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.20% in the past 14 days, which was higher than the 57.23% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $12.47, while its 200-day Moving Average is $12.75. However, in the short run, Zymeworks BC Inc’s stock first resistance to watch stands at $12.41. Second resistance stands at $12.65. The third major resistance level sits at $13.03. If the price goes on to break the first support level at $11.79, it is likely to go to the next support level at $11.41. Assuming the price breaks the second support level, the third support level stands at $11.17.

Zymeworks BC Inc (NASDAQ: ZYME) Key Stats

There are 69,577K outstanding shares of the company, which has a market capitalization of 852.99 million. As of now, sales total 76,300 K while income totals -122,700 K. Its latest quarter income was 31,030 K while its last quarter net income were -23,510 K.